CDK2 and hepatocellular carcinoma: In HCC, CDK2, CDK4, and CDK6 have been shown to be elevated in 84% (Li et al. 2002), 66.7% (Kim et al. 2000), and 46% (Che et al. 2012) of clinical patient samples, respectively.